United Therapeutics announces submission of pre-MAA for implantable drug infusion system
United Therapeutics announced that Medtronic has submitted a pre-market approval application to the FDA for use of Medtronic's SynchroMed® II implantable drug infusion system for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with PAH.
December 24, 2014